Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.

Gerding, Dale N

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. [electronic resource] - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 08 2018 - 649-656 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1537-6591

10.1093/cid/ciy171 doi


Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Anti-Bacterial Agents--therapeutic use
Antibodies, Monoclonal--therapeutic use
Antibodies, Neutralizing--therapeutic use
Broadly Neutralizing Antibodies
Clostridioides difficile--drug effects
Clostridium Infections--mortality
Fecal Microbiota Transplantation
Female
Fidaxomicin--administration & dosage
Humans
Male
Metronidazole--administration & dosage
Middle Aged
Patient Readmission
Recurrence
Risk Factors
Secondary Prevention
Vancomycin--administration & dosage
Young Adult